xxx
 
Print This Page
Share this page: More
 

GLIADEL® Wafers

What is the GLIADEL® wafer?

GLIADEL® wafer

The GLIADEL® wafer is a biodegradable polymer loaded with the chemotherapeutic agent BCNU used for the treatment of recurrent gliomas. It was approved by the FDA in 1995.

After surgical removal of the brain tumor, GLIADEL® wafers are soaked with a chemotherapy drug (BCNU) and are implanted in the space where the tumor was. The wafers destroy the remaining tumor cells.

This is a local drug delivery technique that eliminates the side effects of systemic chemotherapy. Standard chemotherapy affects cancer cells and healthy cells and can cause side effects like fatigue and hair loss.

 

Ranked #1 Neurology & Neurosurgery in the US

US News and World Report Best HospitalsJohns Hopkins Hospital has earned the top spot in US News News & World Report's annual rankings of American hospitals — for the 21st year in a row. Johns Hopkins Neurology and Neurosurgery is also ranked #1 in the nation.

 

National Cancer Institute Comprehensive Cancer Center

The Johns Hopkins Comprehensive Brain Tumor Center is a National Cancer Institute (NCI) designated Comprehensive Cancer Center.
NCI designated Comprehensive Cancer Canter

 

Related Articles

The Hunt for a Brain Tumor Vaccine

Letting the Hounds Loose on Brain Tumors

Turning the Tables on Brain Tumors

Make a Gift - Find Out More

Out-of-State and International Patients - Find Out More

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System, All rights reserved.

Privacy Policy and Disclaimer